ORAL NONPEPTIDE GLP-1 RECEPTOR AGONIST VCT220 FOR OBESITY TREATMENT: A RANDOMIZED, DOUBLE-BLIND, PHASE II TRIAL

Descargar Publicación
Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN) Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP‑1 receptor agonist use